Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Total Non-Current Liabilities (2016 - 2022)

vTv Therapeutics' Total Non-Current Liabilities history spans 9 years, with the latest figure at $13.1 million for Q1 2022.

  • For Q1 2022, Total Non-Current Liabilities rose 27.19% year-over-year to $13.1 million; the TTM value through Mar 2022 reached $13.1 million, up 27.19%, while the annual FY2021 figure was $9.0 million, 17.87% down from the prior year.
  • Total Non-Current Liabilities for Q1 2022 was $13.1 million at vTv Therapeutics, up from $9.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $43.2 million in Q2 2018 and bottomed at $8.3 million in Q3 2021.
  • The 5-year median for Total Non-Current Liabilities is $16.8 million (2020), against an average of $19.9 million.
  • The largest annual shift saw Total Non-Current Liabilities skyrocketed 44.95% in 2018 before it plummeted 49.82% in 2019.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $28.7 million in 2018, then plummeted by 37.75% to $17.8 million in 2019, then plummeted by 38.66% to $10.9 million in 2020, then dropped by 17.87% to $9.0 million in 2021, then soared by 46.17% to $13.1 million in 2022.
  • Per Business Quant, the three most recent readings for VTVT's Total Non-Current Liabilities are $13.1 million (Q1 2022), $9.0 million (Q4 2021), and $8.3 million (Q3 2021).